Randomized pilot study of cabergoline, a dopamine receptor agonist: Effects on body weight and glucose tolerance in obese adults

Diabetes, Obesity and Metabolism

Volumn 14, Issue 4, 2012, Pages 335-340

  Gibson, C D ^a   Karmally, W ^b   Mcmahon, D J ^c   Wardlaw, S L ^c   Korner, J ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Clinical trial; Glycaemic control; Insulin resistance; Randomised trial; Weight loss therapy

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR; GLUCOSE; INSULIN; PLACEBO; PROLACTIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

EID: 84858007570     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01534.x     Document Type: Article

References (44)

1. Rada P, Bocarsly ME, Barson JR, Hoebel BG, Leibowitz SF. Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet. Physiol Behav 2010; 101: 394-400.
2. Levin BE, Dunn-Meynell AA. Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Am J Physiol 1997; 272: R1365-R1370.
3. Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci 2010; 30: 13105-13109.
4. Wang GJ, Volkow ND, Logan J et al. Brain dopamine and obesity. Lancet 2001; 357: 354-357.
5. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995; 3(Suppl. 4): 515S-523S.
6. Henderson DC. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep 2002; 2: 135-140.
7. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62(Suppl. 7): 22-31.
8. Heffner TG, Zigmond MJ, Stricker EM. Effects of dopaminergic agonists and antagonists of feeding in intact and 6-hydroxydopamine-treated rats. J Pharmacol Exp Ther 1977; 201: 386-399.
9. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
10. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007; 68: 1226-1229.
11. Reis FM, Reis AM, Coimbra CC. Effects of hyperprolactinaemia on glucose tolerance and insulin release in male and female rats. J Endocrinol 1997; 153: 423-428.
12. Serri O, Beauregard H, Rasio E, Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 1986; 45: 572-574.
13. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48: 547-553.
14. Doknic M, Pekic S, Zarkovic M et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147: 77-84.
15. Strader AD, Buntin JD. Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hyperphagia. J Neuroendocrinol 2003; 15: 1046-1053.
16. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71: 68-78.
17. Augustine RA, Grattan DR. Induction of central leptin resistance in hyperphagic pseudopregnant rats by chronic prolactin infusion. Endocrinology 2008; 149: 1049-1055.
18. Asai-Sato M, Okamoto M, Endo M et al. Hypoadiponectinemia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006; 53: 555-562.
19. Kok P, Roelfsema F, Frolich M, Meinders AE, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004; 89: 4445-4449.
20. Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998; 68: 1-10.
21. Luo S, Liang Y, Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology 1999; 69: 160-166.
22. Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels-long-term follow-up in childhood. J Pediatr Endocrinol Metab 2005; 18: 921-924.
23. Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2010; 3: 43-48.
24. Meier AH, Cincotta AH, Lovell WC. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 1992; 48: 248-253.
25. Kamath V, Jones CN, Yip JC et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997; 20: 1697-1701.
26. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19: 667-670.
27. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010; 12: 1048-1057.
28. De Rosa M, Colao A, Di Sarno A et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-293.
29. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331: 904-909.
30. Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2010; 14: 199-207.
31. Dos Santos Silva CM, Barbosa FR, Lima GA et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19: 800-805.
32. Korner J, Lo J, Freda PU, Wardlaw SL. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res 2003; 11: 311-312.
33. Cincotta AH, Meier AH, Cincotta M Jr. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs 1999; 8: 1683-1707.
34. Pijl H, Ohashi S, Matsuda M et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161.
35. Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004; 62: 55-59.
36. Wasada T, Kawahara R, Iwamoto Y. Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients. Diabetes Care 2000; 23: 1039-1040.
37. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009; 12: 96-104.
38. Creemers LB, Zelissen PM. van't Verlaat JW, Koppeschaar HP, Prolactinoma and body weight: a retrospective study. Acta Endocrinol 1991; 125: 392-396.
39. USFDA. Cycloset prescribing information. Available from URL:. Accessed 21 December 2011.
40. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
41. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
42. Gaziano JM, Cincotta AH, O'Connor CM et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010; 33: 1503-1508.
43. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
44. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46.